Anti-Cholinesterase Combination Drug Therapy as a Potential Treatment for Alzheimer’s Disease

Amat-ur-Rasool, Hafsa; Ahmed, Mehboob; Hasnain, Shahida; Carter, Wayne G.

doi:10.3390/brainsci11020184

All Outputs (3)

In Silico Design of Dual-Binding Site Anti-Cholinesterase Phytochemical Heterodimers as Treatment Options for Alzheimer’s Disease (2021)
Journal Article

The number of patients with neurodegenerative diseases, particularly Alzheimer’s disease (AD), continues to grow yearly. Cholinesterase inhibitors (ChEIs) represent the first-line symptomatic drug treatment for mild-to-moderate AD; however, there is... Read More about In Silico Design of Dual-Binding Site Anti-Cholinesterase Phytochemical Heterodimers as Treatment Options for Alzheimer’s Disease.

The Neuroprotective Effects of Cannabis-Derived Phytocannabinoids and Resveratrol in Parkinson’s Disease: A Systematic Literature Review of Pre-Clinical Studies (2021)
Journal Article

Currently, there are no pharmacological treatments able to reverse nigral degeneration in Parkinson’s disease (PD), hence the unmet need for the provision of neuroprotective agents. Cannabis-derived phytocannabinoids (CDCs) and resveratrol (RSV) may... Read More about The Neuroprotective Effects of Cannabis-Derived Phytocannabinoids and Resveratrol in Parkinson’s Disease: A Systematic Literature Review of Pre-Clinical Studies.

Anti-Cholinesterase Combination Drug Therapy as a Potential Treatment for Alzheimer’s Disease (2021)
Journal Article

Alzheimer’s disease (AD) is a burgeoning social and healthcare problem. Cholinesterase inhibitors (ChEIs) are employed for symptomatic treatment of AD, but often elicit adverse drug reactions (ADRs). Herein, the potency of the ChEIs, donepezil, tacri... Read More about Anti-Cholinesterase Combination Drug Therapy as a Potential Treatment for Alzheimer’s Disease.